• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 2 of 24

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10Next >End >>
15.03.2022Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

In The News

08.03.2022MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease

Press Release

09.03.2022Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

Press Release

18.02.2022 Nalu Medical Inc. Announces $104 Million Equity Financing

Press Release

16.02.2022Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

Press Release

11.01.2022Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics

Press Release

15.12.2021Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Press Release

06.12.2021Amphista Therapeutics Appoints Dr Martin Pass as CDO

Press Release

02.12.2021AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

Press Release

02.12.2021Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences